Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Versameb AG maintains a patent portfolio within the Biotechnology & Pharmaceuticals technology area. The current prosecution landscape is defined by 1 pending office action, which represents the entirety of the company's active engagement with the patent office. This matter is assigned to 1 distinct examiner, SULLIVAN, STEPHANIE LAUREN, who serves as the busiest examiner for the portfolio. SULLIVAN, STEPHANIE LAUREN currently oversees the pending office action, representing the total active volume for the company.
The administrative footprint of the portfolio is limited to a distinct art unit. This level of concentration means that the company's immediate patent outcomes are tied to the specific examination practices of the assigned individual and the technical group within the Biotechnology & Pharmaceuticals field. For a practitioner, this indicates a lack of diversification across different examiners or art units, making the specific preferences and history of SULLIVAN, STEPHANIE LAUREN the primary factor in current prosecution success. The focused nature of this portfolio requires a strategy tailored to the specific precedents and tendencies of the assigned examiner and the administrative standards of the art unit.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SULLIVAN, STEPHANIE LAUREN | 1 | 58.1% | +40.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17348876 | RNA ENCODING A PROTEIN WITH A HETEROLOGOUS SIGNAL PEPTIDE | SULLIVAN, STEPHANIE LAUREN | 89d overdue |
| Art Unit | Apps |
|---|---|
| 1635 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17348876 | RNA ENCODING A PROTEIN WITH A HETEROLOGOUS SIGNAL PEPTIDE | SULLIVAN, STEPHANIE LAUREN | 1635 | §103 | Final Rejection | 89d overdue | Pending | Jun 16, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial